{"entity":{"id":"nct05755113","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","aka":[],"tldr":"A phase 2 trial of Tigilanol Tiglate in sarcomas, run by QBiotics Group Limited, now recruiting.","summary":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT05755113 by QBiotics Group Limited, with 40 participants planned, started 2023-04-13 and due to reach its primary completion in 2027-01. Interventions recorded: Tigilanol Tiglate.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05755113","url":"https://clinicaltrials.gov/study/NCT05755113"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["qbiotics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05755113","phase":"2","setting":"A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.","sponsor":"QBiotics Group Limited","enrolled":40,"outcomes":[]},"route":"/trials/nct05755113/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"company":[{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/"}]}}